Analyte News and Research

RSS

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Waters Corporation today introduced the SYNAPT® G2-S High Definition Mass Spectrometer, representing a significant step forward in performance for High Definition Mass Spectrometry. The SYNAPT G2-S incorporates both high-sensitivity Waters StepWave™ ion transfer optics and Triwave® ion mobility technologies along with a suite of new informatics tools to take qualitative and quantitative high resolution performance to a new level.

6 Jun 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Practical solutions for translational science from Randox Laboratories

The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering.

From Randox Laboratories Ltd. 23 May 2011

Health Canada grants SQI license to market IgX PLEX Celiac Panel

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it has received a license from Health Canada permitting the Company to market its IgX PLEX™ Celiac Panel, a quantitative 4-plex panel, which will run on SQI's automated SQiDworks™ Diagnostics Platform.

29 Apr 2011

GSN receives NIH grant for non-invasive prenatal test trial in genetic abnormalities

Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.

28 Apr 2011

T2 Biosystems' technology platform demonstrates ability to detect Candida organisms in whole blood samples

T2 Biosystems, Inc., a company developing next-generation diagnostic products, presented data today on the rapid and sensitive detection of five species of the fungal infection Candida at the Annual Meeting of the Mycoses Study Group in Philadelphia, PA.

8 Apr 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million in cash, providing QIAGEN with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.

From QIAGEN Manchester Limited 4 Apr 2011

Non-invasive blood glucose monitor closer to market

People with diabetes could soon have a pain-free way to check their blood glucose levels. Researchers at the University of Missouri–St. Louis have developed a portable, inexpensive non-invasive blood glucose detector. The university has licensed patent rights for the device to St. Louis Medical Devices, Inc., a Missouri company headquartered at UMSL’s own startup company incubator – IT Enterprises, to bring the device to market.

30 Mar 2011

CALP, HistoRx collaborate to co-develop new generation of tissue-based imaging solutions

Caliper Life Sciences, Inc. and HistoRx, Inc., today announced a collaboration to co-develop a new generation of tissue-based imaging and analysis solutions, based on immuno-fluorescence, that will deliver accurate, quantitative, and reproducible measurements of proteins in tissue samples.

11 Mar 2011

Wako i30 Immunoanalyzer incorporating Caliper's microfluidic LabChip technologies receives 510(k) clearance

Caliper Life Sciences, Inc. today announced that its licensee Wako Pure Chemical Industries, through its Wako Diagnostics division, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its uTASWako® i30 Immunoanalyzer and AFP-L3 and DCP Assays, which are used to assess liver cancer risk in patients with chronic liver disease.

4 Mar 2011

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA.

2 Mar 2011

Quanterix expands its Single Molecule Array technology to measure proteins precisely

Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array technology by combining digital and analog detection in one straightforward measurement.

24 Feb 2011

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

MedTrust Online and Avantra Biosciences announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx multiplex immunoassay system.

22 Feb 2011

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Avantra Biosciences today announced the selection of TGen Drug Development as a key test site for Avantra's new biomarker quantitation platform.

1 Feb 2011

Avantra begins shipment of new Q400 Biomarker Workstation and Angio Qx BioChip Immunoassay

Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx™ BioChip Immunoassay.

27 Jan 2011

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

The Spinal Muscular Atrophy Foundation and Rules-Based Medicine, announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM's Multi-Analyte Profiling technology platform.

21 Jan 2011

PAM50 test is now available to classify breast cancer subtypes

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.

18 Jan 2011

Caliper launches new LabChip Dx system for clinical research laboratories

Caliper Life Sciences, today announced the launch of Caliper's new, innovative LabChip Dx system for use by clinical research laboratories developing molecular diagnostic tests.

11 Jan 2011

International reference standards for use of bone turnover markers in clinical studies recommended

An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and recommends that specific markers be used as reference analytes for BTMs in clinical and observational studies.

28 Dec 2010

Response Biomedical strengthens patent protection for RAMP technology

Response Biomedical Corporation today announced that the United States Patent and Trademark Office issued an official Notice of Allowance on one of the Company's patent applications regarding the RAMP® technology. The patent entitled "Comparative Multiple Analyte Immunoassay" is expected to issue in the first quarter of 2011.

20 Dec 2010